DeepMed Research

Onconic Therapeutics Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Phase 3

Recruiting

Conditions: Peptic Ulcer

Interventions: Drug: Lanston Capsule 15 mg
Drug: JP-1366 10 mg
Drug: Lanston Capsule 15 mg placebo
Drug: JP-1366 10 mg placebo

First Posted Date: 2024-06-03

Last Posted Date: 2024-11-01

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 364

Registration Number: NCT06439563

Locations: 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JP-1366 20mg tablet
Drug: JP-1366 20mg capsule

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-20

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 30

Registration Number: NCT05814809

Locations: 🇰🇷
Yangji Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JP-1366 20mg tablet

First Posted Date: 2023-02-03

Last Posted Date: 2024-08-26

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 24

Registration Number: NCT05712681

Locations: 🇰🇷
Asan Medical Central, Seoul, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: JPI-547

First Posted Date: 2022-07-26

Last Posted Date: 2024-08-27

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 58

Registration Number: NCT05475184

Locations: 🇰🇷
National Cancer Center, Gyeonggi-do, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Phase 3

Completed

Conditions: Gastric Ulcer

Interventions: Drug: Lansoprazole 30mg
Drug: JP-1366 20mg

First Posted Date: 2022-07-07

Last Posted Date: 2024-08-26

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 329

Registration Number: NCT05448001

Locations: 🇰🇷
Korea University Kuro Hospital, Seoul, Korea, Republic of

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Phase 3

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: JP-1366 20mg
Drug: Esomeprazole 40mg

First Posted Date: 2022-07-05

Last Posted Date: 2024-08-27

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 300

Registration Number: NCT05443984

Locations: 🇰🇷
Asan Medical Center and 26 hospitals, Seoul, Korea, Republic of

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: JPI-547
Drug: modified FOLFIRINOX
Drug: Gemcitabine-nab-paclitaxel

First Posted Date: 2022-02-25

Last Posted Date: 2025-02-19

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 30

Registration Number: NCT05257993

Locations: 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

and more 1 locations

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

Phase 1

Completed

Conditions: Helicobacter Pylori Associated Gastrointestinal Disease

Interventions: Drug: JP-1366 20mg 1capsule
Drug: Amoxicillin 500Mg Cap
Drug: Clarithromycin 500Mg Tab

First Posted Date: 2022-01-18

Last Posted Date: 2022-01-18

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 29

Registration Number: NCT05194046

Locations: 🇰🇷
Cha University Bundang Medical Center, Gyeonggi-do, Korea, Republic of

Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

Phase 1

Completed

Conditions: Anti-Ulcer Agents

Interventions: Drug: coadministration of JP-1366 and aceclofenac
Drug: coadministration of JP-1366 and meloxicam
Drug: coadministration of JP-1366 and naproxen
Drug: single-dosing of JP-1366 in Korean and Caucasian

First Posted Date: 2022-01-06

Last Posted Date: 2022-06-30

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 88

Registration Number: NCT05181124

Locations: 🇰🇷
Cha University Bundang Medical Center, Gyeonggi-do, Korea, Republic of

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: JPI-547

First Posted Date: 2020-04-06

Last Posted Date: 2022-06-03

Lead Sponsor: Onconic Therapeutics Inc.

Target Recruit Count: 62

Registration Number: NCT04335604

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University College of Medicine, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy